C4 Therapeutics/CCCC

$9.51

4.22%
-
1D1W1MYTD1YMAX

About C4 Therapeutics

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. It leverages its technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to design and optimize small-molecule medicines that harness the body's natural protein recycling system to rapidly degrade disease-causing proteins. Its TORPEDO platform enables the discovery of targeted investigational small molecule medicines called protein degraders. Its advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma (MM), and non-Hodgkin lymphomas (NHLs). Its other product candidate, CFT8634, is an orally bioavailable BiDAC degrader of a protein target called BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors.

Ticker

CCCC

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Andrew Hirsch

Employees

145

Headquarters

Watertown, United States

C4 Therapeutics Metrics

BasicAdvanced
$616.72M
Market cap
-
P/E ratio
-$2.67
EPS
3.12
Beta
-
Dividend rate

What the Analysts think about C4 Therapeutics

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
91.9% upside
High $60.00
Low $7.00
$9.51
Current price
$18.25
Average price target

C4 Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,084.37% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$3.2M
-70.91%
Net income
$-34.7M
28.52%
Profit margin
-1,084.37%
341.79%

C4 Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.67%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
-$0.71
-$0.73
-$0.55
-
Expected
-$0.75
-$0.69
-$0.66
-$0.36
Surprise
-4.79%
6.14%
-16.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell C4 Therapeutics stock

Buy or sell C4 Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing